Literature DB >> 4436788

Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.

C Pantarotto, A Bossi, G Belvedere, A Martini, M G Donelli, A Frigerio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4436788     DOI: 10.1002/jps.2600631014

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  11 in total

1.  Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide.

Authors:  C T Evelo; R P Bos; J G Peters; P T Henderson
Journal:  Int Arch Occup Environ Health       Date:  1986       Impact factor: 3.015

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  A procedure for monitoring cyclophosphamide and isophosphamide in biological samples.

Authors:  B Whiting; S H Miller; B Caddy
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

4.  Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.

Authors:  G Edwards; R T Calvert; D Crowther; V Bramwell; H Scarffe
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

5.  Detection of contamination with antineoplastic agents in a hospital pharmacy department.

Authors:  P J Sessink; R B Anzion; P H Van den Broek; R P Bos
Journal:  Pharm Weekbl Sci       Date:  1992-02-21

6.  The disposition of cyclophosphamide in a group of myeloma patients.

Authors:  V Bramwell; R T Calvert; G Edwards; H Scarffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.

Authors:  T Cerny; A Graf; P Rohner; T Zeugin; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

Authors:  F D Juma; H J Rogers; J R Trounce; I D Bradbrook
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

10.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.